Although drug-eluting stents are still the default interventional treatment of coronary artery
disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in …

Percutaneous coronary intervention with a drug-eluting stent is the most common mode of
revascularization for coronary artery disease. However, restenosis rates remain high. Non …

Background In the treatment of de-novo coronary small vessel disease, drug-coated
balloons (DCBs) are non-inferior to drug-eluting stents (DESs) regarding clinical outcome up …

In-stent restenosis (ISR) remains the most common cause of stent failure after percutaneous
coronary intervention (PCI). Recent data suggest that ISR-PCI accounts for 5-10% of all PCI …

Background In patients with coronary in-stent restenosis (ISR) requiring reintervention, it is
unclear if the choice of treatment should depend on whether the restenotic stent was a bare …

Aims The best interventional strategy for the treatment of drug-eluting stent (DES) in-stent
restenosis (ISR) is still unclear and no data from randomized trials beyond 3-year follow-up …

Percutaneous coronary intervention (PCI) continues to advance at pace with an ever-
broadening indication. In this article we will review the recent technological advances in PCI …

Drug-coated balloon (DCB) technology was developed to deliver the antiproliferative drugs
to the vessel wall without leaving any permanent prosthesis or durable polymers. The …

I. Introduction The anatomic and clinical complexity of patients with coronary artery disease
(CAD) is increasing in the United States. 1–3 While the terms “complex CAD” or “high-risk …

Advances in stent technology and the design of endovascular devices with thinner struts,
anti‐inflammatory and antithrombotic polymers, and better drug kinetics have enhanced the …